Cascadian Therapeutics Company Profile (NASDAQ:CASC)

About Cascadian Therapeutics (NASDAQ:CASC)

Cascadian Therapeutics logoCascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CASC
  • CUSIP: 68232410
  • Web: www.cascadianrx.com
Capitalization:
  • Market Cap: $206.79 million
  • Outstanding Shares: 49,235,000
Average Prices:
  • 50 Day Moving Avg: $4.15
  • 200 Day Moving Avg: $4.02
  • 52 Week Range: $3.49 - $10.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.08
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.30 per share
  • Price / Book: 1.27
Profitability:
  • EBIDTA: ($41,450,000.00)
  • Return on Equity: -43.55%
  • Return on Assets: -38.89%
Debt:
  • Current Ratio: 9.93%
  • Quick Ratio: 9.93%
Misc:
  • Average Volume: 172,208 shs.
  • Beta: 2.29
  • Short Ratio: 8.29
 

Frequently Asked Questions for Cascadian Therapeutics (NASDAQ:CASC)

What is Cascadian Therapeutics' stock symbol?

Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."

How were Cascadian Therapeutics' earnings last quarter?

Cascadian Therapeutics Inc (NASDAQ:CASC) announced its earnings results on Tuesday, May, 9th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.09. View Cascadian Therapeutics' Earnings History.

Where is Cascadian Therapeutics' stock going? Where will Cascadian Therapeutics' stock price be in 2017?

4 analysts have issued twelve-month price objectives for Cascadian Therapeutics' shares. Their predictions range from $4.00 to $10.00. On average, they anticipate Cascadian Therapeutics' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Cascadian Therapeutics.

What are analysts saying about Cascadian Therapeutics stock?

Here are some recent quotes from research analysts about Cascadian Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company's product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. " (5/19/2017)
  • 2. Cantor Fitzgerald analysts commented, "HER2CLIMB Is the Main Focus. Phase II HER2CLIMB study will include a triplet combination" (tucatinib, Herceptin, and Xeloda) in patients with previously treated, unresectable HER2-positive metastatic breast cancer. The trial will enroll 480 patients, expanded from the original expectation of 180, though PFS will remain the primary endpoint." (5/10/2017)
  • 3. Cowen and Company analysts commented, "CASC reported 1Q financials and provided a pipeline update." (5/9/2017)

Who are some of Cascadian Therapeutics' key competitors?

Who owns Cascadian Therapeutics stock?

Cascadian Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (18.42%), Baupost Group LLC MA (17.71%), Redmile Group LLC (8.27%), Vanguard Group Inc. (2.89%), Sphera Funds Management LTD. (1.18%) and Sandia Holdings LLC (1.10%). Company insiders that own Cascadian Therapeutics stock include Christopher S Henney, Diana Hausman, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Institutional Ownership Trends for Cascadian Therapeutics.

Who bought Cascadian Therapeutics stock? Who is buying Cascadian Therapeutics stock?

Cascadian Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Baupost Group LLC MA, Redmile Group LLC, Vanguard Group Inc., Sphera Funds Management LTD., Goldman Sachs Group Inc., Sabby Management LLC and Geode Capital Management LLC. Company insiders that have bought Cascadian Therapeutics stock in the last two years include Christopher S Henney, Diana Hausman, Gwen A Fyfe, Scott Dunseth Myers and Ted W Love. View Insider Buying and Selling for Cascadian Therapeutics.

How do I buy Cascadian Therapeutics stock?

Shares of Cascadian Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cascadian Therapeutics stock cost?

One share of Cascadian Therapeutics stock can currently be purchased for approximately $4.20.

Analyst Ratings

Consensus Ratings for Cascadian Therapeutics (NASDAQ:CASC) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $7.00 (66.67% upside)

Analysts' Ratings History for Cascadian Therapeutics (NASDAQ:CASC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Cantor FitzgeraldReiterated RatingHold$4.00LowView Rating Details
5/9/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
4/21/2017BTIG ResearchInitiated CoverageBuyHighView Rating Details
3/11/2017Jefferies Group LLCReiterated RatingBuy$15.00 -> $10.00N/AView Rating Details
3/15/2016Raymond James Financial, Inc.Lower Price Target$5.00 -> $3.00N/AView Rating Details
12/9/2015HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Cascadian Therapeutics (NASDAQ:CASC)
Earnings by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Earnings History by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.39)($0.30)ViewListenView Earnings Details
3/9/2017Q4 2016($0.52)($0.47)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.08)($0.09)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.10)($0.14)ViewN/AView Earnings Details
3/14/2016Q4($0.08)($0.10)ViewN/AView Earnings Details
11/5/2015Q315($0.10)($0.05)ViewListenView Earnings Details
8/6/2015Q215($0.08)($0.11)ViewN/AView Earnings Details
5/11/2015Q115($0.08)($0.08)ViewListenView Earnings Details
3/10/2015Q414($0.09)($0.30)ViewListenView Earnings Details
11/6/2014Q314($0.11)($0.09)ViewN/AView Earnings Details
8/11/2014Q214($0.13)($0.09)ViewN/AView Earnings Details
5/1/2014Q114($0.12)($0.14)ViewN/AView Earnings Details
3/13/2014Q413($0.10)($0.09)ViewN/AView Earnings Details
11/12/2013Q3($0.11)($0.12)ViewListenView Earnings Details
8/6/2013Q2 2013($0.14)($0.28)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.13)($0.14)ViewN/AView Earnings Details
3/25/2013Q412$1.09$0.50$135.60 million$123.57 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.16)($0.12)ViewN/AView Earnings Details
11/28/20121.16$1.16$137.19 millionViewN/AView Earnings Details
11/7/2012Q312($0.15)($0.15)ViewN/AView Earnings Details
8/9/2012($0.15)($0.15)ViewN/AView Earnings Details
5/7/2012($0.17)$0.21ViewN/AView Earnings Details
3/6/2012($0.15)($0.27)ViewN/AView Earnings Details
11/8/2011($0.16)$0.22ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cascadian Therapeutics (NASDAQ:CASC)
Current Year EPS Consensus Estimate: $5.02 EPS
Next Year EPS Consensus Estimate: $-1.03 EPS

Dividends

Dividend History for Cascadian Therapeutics (NASDAQ:CASC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cascadian Therapeutics (NASDAQ:CASC)
Insider Ownership Percentage: 20.70%
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Insider Trades by Quarter for Cascadian Therapeutics (NASDAQ:CASC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Scott Dunseth MyersInsiderBuy2,800$4.00$11,200.00View SEC Filing  
3/31/2017Scott Dunseth MyersInsiderBuy2,000$4.11$8,220.00View SEC Filing  
3/28/2017Gwen A FyfeDirectorBuy1,666$4.12$6,863.92View SEC Filing  
3/20/2017Scott Dunseth MyersInsiderBuy1,000$3.93$3,930.00View SEC Filing  
2/2/2017Ted W. LoveDirectorBuy23,000$4.24$97,520.00View SEC Filing  
1/30/2017Christopher S HenneyDirectorBuy25,324$4.11$104,081.64View SEC Filing  
1/27/2017Scott Dunseth MyersInsiderBuy20,500$3.76$77,080.00View SEC Filing  
8/17/2016Scott Dunseth MyersInsiderBuy45,000$1.15$51,750.00View SEC Filing  
6/28/2016Scott Dunseth MyersCEOBuy62,500$0.80$50,000.00View SEC Filing  
6/1/2015Diana HausmanInsiderBuy5,747$4.65$26,723.55View SEC Filing  
3/26/2015Daniel K SpiegelmanDirectorBuy10,000$1.59$15,900.00View SEC Filing  
3/25/2015Daniel K SpiegelmanDirectorBuy10,000$1.63$16,300.00View SEC Filing  
12/17/2014Bvf Partners L P/IlMajor ShareholderBuy378,444$1.82$688,768.08View SEC Filing  
12/15/2014Bvf Partners L P/IlMajor ShareholderBuy224,949$1.88$422,904.12View SEC Filing  
9/23/2014Jay VenkatesanEVPBuy250,000$2.00$500,000.00View SEC Filing  
7/10/2014Daniel K SpiegelmanDirectorSell3,403$1.72$5,853.16View SEC Filing  
2/20/2014Daniel K SpiegelmanDirectorSell12,780$1.96$25,048.80View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy129,000$1.78$229,620.00View SEC Filing  
8/8/2013Bvf Partners P/Ilmajor shareholderBuy258,361$1.65$426,295.65View SEC Filing  
8/1/2013Bvf Partners L P/IlMajor ShareholderBuy338,087$1.74$588,271.38View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy214,467$1.81$388,185.27View SEC Filing  
12/27/2012Wendy W WarrenMajor ShareholderSell57,943$64.30$3,725,734.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cascadian Therapeutics (NASDAQ:CASC)
Latest Headlines for Cascadian Therapeutics (NASDAQ:CASC)
Source:
DateHeadline
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 19 at 5:20 PM
americanbankingnews.com logoInsider Buying: Cascadian Therapeutics Inc (CASC) Insider Buys 2,800 Shares of Stock
www.americanbankingnews.com - May 16 at 8:44 PM
americanbankingnews.com logoBrokers Offer Predictions for Cascadian Therapeutics Inc's FY2017 Earnings (CASC)
www.americanbankingnews.com - May 15 at 8:50 AM
americanbankingnews.com logo Brokerages Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.26 EPS
www.americanbankingnews.com - May 12 at 4:02 PM
News IconCORRECTED-BRIEF-Cascadian says stockholder Growth Equity Opportunities Fund IV has option to resell 1.82 mln of co's shares (May 8)
www.businessinsider.com - May 11 at 2:22 AM
reuters.com logoBRIEF-Cascadian Therapeutics reports Q1 loss per share of $0.30 - Reuters
www.reuters.com - May 10 at 8:33 AM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Earns Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 10 at 7:36 AM
finance.yahoo.com logoEdited Transcript of CASC earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - May 9 at 9:09 PM
americanbankingnews.com logoCascadian Therapeutics' (CASC) "Buy" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - May 9 at 6:24 PM
globenewswire.com logoCascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 ... - GlobeNewswire (press release)
globenewswire.com - May 9 at 4:08 PM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Announces Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 9 at 1:38 PM
marketbeat.com logoCascadian Therapeutics reports 1Q loss
marketbeat.com - May 9 at 10:27 AM
finance.yahoo.com logoCascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET
finance.yahoo.com - May 9 at 8:25 AM
finance.yahoo.com logoInvestor Network: Cascadian Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 8:25 AM
bizjournals.com logoArray BioPharma Announces Strategic Collaboration with Merck
www.bizjournals.com - May 8 at 10:12 AM
globenewswire.com logoCascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017 - GlobeNewswire (press release)
globenewswire.com - May 3 at 8:20 AM
finance.yahoo.com logoCascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017
finance.yahoo.com - May 1 at 4:08 PM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Now Covered by BTIG Research
www.americanbankingnews.com - April 21 at 11:08 PM
americanbankingnews.com logoCascadian Therapeutics Inc (CASC) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 21 at 10:48 PM
seekingalpha.com logoAbout: Cascadian Therapeutics, (CASC) - Seeking Alpha
seekingalpha.com - March 24 at 4:28 PM
finance.yahoo.com logoCASCADIAN THERAPEUTICS, INC. Financials
finance.yahoo.com - March 15 at 4:30 PM
nasdaq.com logoCascadian Therapeutics Announces Changes to Board of Directors - Nasdaq
www.nasdaq.com - March 14 at 4:02 PM
reuters.com logoBRIEF-Cascadian Therapeutics appoints Robert Azelby to the board
www.reuters.com - March 14 at 11:02 AM
us.rd.yahoo.com logo4:02 pm Cascadian Therapeutics announces that Robert W. Azelby has been appointed to the Company's Board of Directors
us.rd.yahoo.com - March 14 at 11:02 AM
us.rd.yahoo.com logoCascadian Therapeutics Announces Changes to Board of Directors
us.rd.yahoo.com - March 13 at 4:18 PM
americanbankingnews.com logoJefferies Group Comments on Cascadian Therapeutics Inc’s FY2021 Earnings (CASC)
www.americanbankingnews.com - March 13 at 2:48 PM
nasdaq.com logoCascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results - Nasdaq
www.nasdaq.com - March 10 at 5:05 PM
finance.yahoo.com logoCascadian Therapeutics reports 4Q loss - Yahoo Finance
finance.yahoo.com - March 10 at 5:05 PM
biz.yahoo.com logoCASCADIAN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 9 at 9:44 PM
reuters.com logoBRIEF-Cascadian Therapeutics Q4 loss per share $0.47
www.reuters.com - March 9 at 4:43 PM
finance.yahoo.com logoCascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 9 at 4:43 PM
seekingalpha.com logoCascadian Therapeutics (CASC) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 7 at 4:11 PM
prnewswire.com logoArray BioPharma To Present At The Cowen And Company Annual Healthcare Conference
www.prnewswire.com - March 1 at 10:16 AM
finance.yahoo.com logoCascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 27 at 1:22 PM
prnewswire.com logoHealthcare Stocks on Investors' Radar -- Alkermes, Teleflex, Cascadian Therapeutics, and InspireMD - PR Newswire (press release)
www.prnewswire.com - February 24 at 9:20 PM
biz.yahoo.com logoCASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
biz.yahoo.com - February 8 at 4:23 PM
reuters.com logoBRIEF-Cascadian Therapeutics received a notice from BVF Partners L.P. and others terminating letter agreement
www.reuters.com - February 3 at 9:24 PM
biz.yahoo.com logoCASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
biz.yahoo.com - January 27 at 5:25 PM
seekingalpha.com logoCascadian prices equity offering; shares ease 4% premarket - Seeking Alpha
seekingalpha.com - January 26 at 3:17 AM
reuters.com logoBRIEF-Cascadian Therapeutics prices $82.5 mln concurrent offerings of common stock and preferred stock
www.reuters.com - January 25 at 5:15 PM
biz.yahoo.com logoCASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materia
biz.yahoo.com - January 24 at 9:42 PM
finance.yahoo.com logoCascadian Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
finance.yahoo.com - January 23 at 4:26 PM
biz.yahoo.com logoCASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - January 23 at 4:26 PM
reuters.com logoBRIEF-Mark Lampert says resigning from Cascadian Therapeutics' board - Reuters
www.reuters.com - January 18 at 3:37 PM
reuters.com logoBRIEF-Mark Lampert says resigning from Cascadian Therapeutics' board
www.reuters.com - January 17 at 9:59 PM
globenewswire.com logoCascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and Quality - GlobeNewswire (press release)
globenewswire.com - January 6 at 2:39 AM
finance.yahoo.com logoCascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and Quality - Yahoo Finance
finance.yahoo.com - January 4 at 10:07 PM

Social

Chart

Cascadian Therapeutics (CASC) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff